TOKYO, Jun 17 (Pulse News Wire) – StemRIM Inc. (4599.T) announced today that a patent application related to the use of its regenerative medicine candidate Ledasumitide (HMGB1 fragment peptide) for treating chondral diseases such as traumatic cartilage defects, osteoarthritis, and osteochondritis dissecans was successfully registered in Australia.
Ledasumitide, developed through collaboration with Shionogi & Co., Ltd., is designed to mobilize mesenchymal stem cells (MSCs) from bone marrow into the bloodstream, facilitating their accumulation at injury sites. This process is expected to promote tissue repair and regeneration within damaged knee joints. The patent filing includes partners Osaka University and covers applications in Australia.
"This patent registration strengthens our confidence in developing Ledasumitide-based treatments for chondral diseases in Australia," said Masanobu Okashima, President and CEO of StemRIM. "It underscores our commitment to expanding the therapeutic scope of Ledasumitide." Chondral diseases often lead to chronic pain and joint dysfunction due to limited self-repair capabilities of cartilage. With intravenous administration, Ledasumitide offers a minimally invasive treatment option that could significantly benefit patients in future medical settings.
The company noted that there would be no impact on its fiscal year ending June 2026 performance due to this development but pledged to disclose any significant changes promptly.
🟢 Confidence: High AI-translated content.